AbbVie Inc (ABBV)vsNano X Imaging Ltd (NNOX)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
NNOX
Nano X Imaging Ltd
$1.71
0.00%
HEALTHCARE · Cap: $129.44M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 469603% more annual revenue ($61.16B vs $13.02M). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NNOX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+53.7%
Fair Value
$4.84
Current Price
$1.71
$3.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.0% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NNOX
The strongest argument for NNOX centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : NNOX
The primary concerns for NNOX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while NNOX is a growth play — different risk/reward profiles.
NNOX carries more volatility with a beta of 1.38 — expect wider price swings.
NNOX is growing revenue faster at 24.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 32/100). NNOX offers better value entry with a 53.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Nano X Imaging Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Nano-X Imaging Ltd., a development-stage company, develops, produces and markets digital X-ray source technology for the medical imaging industry globally. The company is headquartered in Neve Ilan, Israel.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?